Dendritic Cell and Cancer Therapy - PMC - PubMed Central (PMC)
Dendritic cells (DCs) are acknowledged as the most potent professional antigen-presenting cells (APCs), able to induce adaptive immunity and support the innate immune response. In this regard, DCs represent a promising means for cancer vaccines to strengthen the anti-cancer immune response to overcome the immunosuppressive tumor microenvironment.
Dendritic cells as orchestrators of anticancer immunity and
Feb 7, 2024 · Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells that regulate adaptive immunity, including against cancer. Therefore, understanding the precise...
Cancer Immunotherapy Breakthrough: Dendritic Cell Vaccines
Jan 24, 2022 · A dendritic cell vaccine is a cross between a vaccine and a cell therapy. These dendritic cells are like immune system factories and make other molecules that activate critical parts of the innate and adaptive immune system.
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies.
Dendritic cells in cancer immunology and immunotherapy
Aug 29, 2019 · Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is...
Recent Progress in Dendritic Cell-Based Cancer Immunotherapy
In this regard, dendritic cells are useful tools to induce host immune responses against exogenous antigens. In particular, recently characterized cross-presenting dendritic cells are capable of inducing CD8+ cytotoxic T-lymphocytes against exogenous antigens such as tumor antigens and uniquely express the chemokine receptor XCR1.
Insights Into Dendritic Cells in Cancer Immunotherapy: From …
Jun 28, 2021 · A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Engineering dendritic cell vaccines to improve cancer ... - Nature
Nov 27, 2019 · At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy.
Advances in Human Dendritic Cell-Based Immunotherapy Against ...
May 10, 2022 · GC remains the fifth most common cancer and the third deadliest cancer worldwide. Chemotherapy, surgery, and radiotherapy are treatment regimens for GC. However, its 5-year survival rate is 20%–30%. Recently, more and more attention is paid to DC-based immunotherapy.
Dendritic Cells and Their Role in Immunotherapy - Frontiers
May 20, 2020 · Dendritic cells have long been a focus of cancer immunotherapy due to their role in inducing protective adaptive immunity, but cancer vaccines have shown limited efficacy in the past.